ACTICOR BIOTECH overview

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the Paris Commercial Court, has declared on January 2, the company in liquidation proceedings. The liquidator is Marc-Antoine Rey, SELARL BDR & Associés, 34 rue Sainte Anne, 75001 Paris, [email protected] In view of this decision by the Paris Commercial Court, Acticor Biotech shares will...

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the Paris Commercial Court has today examined the application for conversion of its receivership into liquidation proceedings. Judgment has been postponed until January 2, 2025, when the court will render its decision. A new press release will be issued at that time. In the meantime,...

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the court-appointed administrator has filed a request with the Paris Commercial Court for the conversion of the Company's receivership proceedings into liquidation proceedings. The court will take place on December 19, 2024. Acticor Biotech will continue to inform the market of the next...

Acticor Biotech updates its glenzocimab clinical development plan for the treatment of cardiovascular emergencies New analyses of ACTISAVE phase 2/3 study show positive trends for glenzocimab in subpopulations of patients Continuation of clinical studies: Phase 2/3 GREEN in Ischemic stroke and Phase 2b LIBERATE in myocardial infarction Launch of GALICE, a Phase 2/3 study in severe ischemic stroke, sponsored by the Hôpital Fondation Adolphe de Rothschild and funded by a public grant (national...

University of Birmingham and Acticor Biotech News Release Limited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attacks February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction. In 2022, the University of Birmingham and...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in the United-States, Europe, Israel and United Kingdom Confirmation of clinical results communication for the second quarter 2024 Paris, France, November 07, 2023 - 08h00 CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the...